Series C · Biotech
Adcendo raises $75m Series C for clinical ADC milestones
Jeito Capital led an oversubscribed round, adding new investors and a board member as Adcendo advanced three oncology programs.
Financing the next clinical readouts
Jeito Capital led Adcendo’s $75 million Series C through its second fund. New investors Vida Ventures, Bpifrance and EIFO joined existing shareholders in the oversubscribed financing. Jeito’s Ksenija Pavletic was appointed to the board.
The round supports upcoming clinical milestones across three antibody-drug conjugate programs: the Tiffany-01 cohort expansion for ADCE-T02, dose escalation and expansion for ADCE-D01, and a dose-escalation study for ADCE-B05. Those plans connect the capital to testing the pipeline in patients; the financing announcement does not establish clinical efficacy.
Funding history
Series C · This round$75M